Infantile-onset glycogen storage disease type II

Similar documents
LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW. Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi

DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE

Pompe. Lysosomal Disorders. Introduction

Carnitine palmitoyl transferase 2 deficiency (CPT2) is a rare inherited disorder that occurs when

Pompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine

Echocardiographic Findings in Pompe s Disease with Left Ventricular Obstruction

The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE

The breakdown of fats to provide energy occurs in segregated membrane-bound compartments

Appropriate Use Criteria for Initial Transthoracic Echocardiography in Outpatient Pediatric Cardiology (scores listed by Appropriate Use rating)

What s New in Newborn Screening?

LIMP BABIES - WHAT MAY THAT MEAN?

Neonatal Hypotonia. Encephalopathy acute No encephalopathy. Neurology Chapter of IAP

Evaluation of the Hypotonic Infant and Child

Neonatal Hypotonia Guideline Prepared by Dan Birnbaum MD August 27, 2012

DNA Day Illinois 2013 Webinar: Newborn Screening and Family Health History. Tuesday, April 16, 2013

Glycogen Storage Disease

Fatty Acid Oxidation Disorders

Spinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting

Neonatal Hypoglycemia. Presented By : Kamlah Olaimat 25\7\2010

Fatty Acid Oxidation Disorders

What s New in Newborn Screening?

Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)

During infancy or early childhood, patients with

How to Recognize a Suspected Cardiac Defect in the Neonate

HYPERTROPHIC CARDIOMYOPATHY

Pompe s Disease and the Effects of Alpha- Glucosidase Deficiency

Understanding Late-Onset Pompe Disease

Clinical Approach to Diagnosis of Lysosomal Storage Diseases

Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet

Intraosseous hemangioma is an uncommon benign

Cardiac Disease in Organic Acidemias

History. History and Physical Exam of the Pediatric Patient. History of Present Illness. Chief Complaint. Past Medical History. Past Medical History

INBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides

Diagnosis, management and new treatments for Spinal Muscular Atrophy Special Focus: SMA Type 1

Fatty Acid Beta-Oxidation Disorders: A Brief Review

PATENT DUCTUS ARTERIOSUS (PDA)

Date of commencement: February Principal Investigator Dr. Jayesh J. Sheth CASE RECORD FORM

Pseudo Heart Disease: 1/5 Norman Bethune Faculty of Medicine, Jilin University, China

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency

Clinical Summaries. CLN1 Disease, infantile onset and others

Genetic Cardiomyopathies

Langerhans Cell Histiocytosis with Anterior Mediastinum, Pulmonary and Liver Involvement: CT Demonstration

Cardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement

Anatomy & Physiology

2. General Cardiac Arrest Protocol Medical Newborn/Neonatal. Protocol 8-3 Resuscitation 4. Medical Supraventricular

PAEDIATRIC ACUTE CARE GUIDELINE. ECG Interpretation

A Lawyer s Perspective on Genetic Screening Performed by Cryobanks

Pathophysiology. Tutorial 1 Genetic Diseases

Learn the steps to identify pediatric muscle weakness and signs of neuromuscular disease.

Hypoglycemia. Objectives. Glucose Metabolism

10/16/2014. CCRN Review - Cardiovascular. CCRN Review - Cardiovascular. CCRN Review - Cardiovascular

2) VSD & PDA - Dr. Aso

Preface Acknowledgments Introduction Introductory Concepts Definitions and Context Chronological Age and Age Groups Why Study These Phenomena?

Obesity in Children. JC Opperman

CongHeartDis.doc. Андрій Миколайович Лобода

Metabolism of pentoses, glycogen, fructose and galactose. Jana Novotna

REQUISITION FORM NOTE: ALL FORMS MUST BE FILLED OUT COMPLETELY FOR SAMPLE TO BE PROCESSED. Last First Last First

PAEDIATRIC ECG Dimosthenis Avramidis, MD.

Syncope Due to Intracavitary Left Ventricular Obstruction Secondary to Giant Esophageal Hiatus Hernia

SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I. December 5, 2012

The Heart of the Matter

A Deficit of ATP-ase Subunit 8: with Contribution for Two New Cases

HISTORY. Question: What type of heart disease is suggested by this history? CHIEF COMPLAINT: Decreasing exercise tolerance.

SWISS SOCIETY OF NEONATOLOGY. Pulmonary complications of congenital listeriosis in a preterm infant

A RARE NEUROLOGICAL PRESENTATION OF SLE. Dr Yoganand M N Dr Prithvi P Nayak

Muscle Metabolism. Dr. Nabil Bashir

WOLFF PARKINSON WHITE SYNDROME. Katarzyna Bigaj PGY-1

The Brain Pathology in Fukuyama Type Congenital Muscular Dystrophy -CT and Autopsy Findings-

RESUME Sep National Medical License, Taiwan Oct Board of Interal Medicine, Taiwan Aug Board of Cardiology, Internal Medicine, Taiwan

Sialic Acid Storage Diseases

Why Cardiac MRI? Presented by:

Infection. Risk factor for infection ACoRN alerting sign with * Clinical deterioration. Problem List. Respiratory. Cardiovascular

Not Your Typical Case of Ketotic Hypoglycemia

Muscle Pathology Surgical Pathology Unknown Conference. November, 2008 Philip Boyer, M.D., Ph.D.

Electrocardiographic Studies in the Patients of Duchenne Muscular Dystrophy

INTRODUCTION. 1.

Disorders of Muscle. Disorders of Muscle. Muscle Groups Involved in Myopathy. Needle Examination of EMG. History. Muscle Biopsy

Tall P waves associated with severe combined electrolyte depletion. Citation Journal of electrocardiology (2014)

Sensory Pathways & Somatic Nervous System. Chapter 15

Hemolytic anemias (2 of 2)

THE VEGETATIVE STATE IN INFANCY AND CHILDHOOD

LAB 4: THE MUSCLE AND CARDIOVASCULAR SYSTEM THE MUSCLE AND CARDIOVASCULAR SYSTEM

Human Genetic Diseases (non mutation)

The diagnostic criteria of multilocular renal cysts

LVH GREY ZONE OF HYPERTROPHIED VENTRICLES

Case 1 A 65 year old college professor came to the neurology clinic referred by her family physician because of frequent falling. She had a history of

NEONATOLOGY Healthy newborn. Neonatal sequelaes

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center

CHEST PAIN IS MY CHILD GOING. Thomas C. Martin MD, FAAP, FACC EMMC Pediatric Cardiology Eastern Maine Medical Center Bangor, Maine

Presentation and investigation of mitochondrial disease in children

Genetics. by their offspring. The study of the inheritance of traits is called.

Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report

No social problems noted No past med hx Mother had spontaneous rupture of fetal membranes SB born on Needed to be resuscitated at birth

Paediatric Cardiac Emergencies - Recognition & Management

Pediatric Advanced Life Support

Rare Diseases Nomenclature and classification

Two Cardiology Zebras ERIC MARTIN MD

PECTUS EXCAVATUM WITH SPONTANEOUS TYPE 1 ECG BRUGADA PATTERN OR BRUGADA LIKE PHENOTYPE: ANOTHER BRUGADA ECG PHENOCOPY

Transcription:

Case Report 379 Infantile-Onset Glycogen Storage Disease Type II (Pompe Disease): Report of a Case with Genetic Diagnosis and Pathological Findings Yao-Tun Teng, MD; Wen-Jen Su, MD; Jia-Wei Hou 1, MD, PhD; Shiu-Feng Huang 2, MD Glycogen storage disease type II (GSD-II), also known as Pompe disease, is a rare autosomial recessive disease due to deficiency of lysosomal acidα-glucosidase (GAA). The infantile-onset form is the most severe, and most patients present with hypotonia and cardiomyopathy in early infancy. We report on a typical case of Pompe disease in a patient who died at 8 months of age due to aspiration pneumonia and hypertrophic cardiomyopathy. Genetic studies showed deficient GAA activity and mutation of the GAA gene with Gly615Arg (exon 13, G1845A). On autopsy, glycogen had markedly accumulated in the liver, myocardium and skeletal muscle. The neurons of the anterior horn of the spinal cord and medulla were also involved, but the cortex was spared. These neurological-histologic findings may explain the clinical features of poor motor function, decreased deep tendon reflexes and lack of mental retardation. (Chang Gung Med J 2004;27:379-84) Key words: pompe disease, autopsy, acid -glucosidase. Infantile-onset glycogen storage disease type II (GSD-II) is one of the causes of infantile sudden death. (1) Affected infants can appear normal at birth, but soon develop generalized muscle weakness, areflexia, macroglossia, hepatomegaly and massive cardiomegaly. Most patients die of cardiorespiratory failure prior to 2 years of age. GSD-II is an autosomal recessive disorder, caused by deficient activity of lysosomal acid α-glucosidase (acid maltase) (GAA). It is an enzyme responsible for the degradation of glycogen in lysosomes. GSD-II encompasses a wide range of clinical phenotypes, which correlate with residual GAA enzyme activity, and the most severe one is the infantile-onset form. In this report, we describe a case of infantile-onset Pompe disease with typical clinical appearance with genetic diagnosis and pathological findings. CASE REPORT A 5 month-old boy was born at full-term by a G2P2 mother. He had a birth body weight of 2750 gm. He had no perinatal insult and had a normal Apgar score 8-9. After birth, frequent respiratory distress, feeding difficulties and poor weight gain were noticed by his parents. He was sent to our hospital because of fever and respiratory distress. On examination, he had a high fever (up to 39 C), and dyspnea, and his blood pressure and pulse 109/84 mmhg and 170/min respectively. He was poorly-nourished with a body weight of 6.6 kg (25th percentile), acyanosis, weak crying, and protruding tongue. Chest examination revealed no significant heart murmur but he had coarse breathing sounds, and his precordial maximal impulse was shifted to left. There From the Division of Pediatric Cardiology and 1 Medical Genetics, Department of Pediatrics, Chang Gung Children's Hospital, Taipei; 2 Departments of Pathology, Chang Gung Memorial Hospital, Taipei. Received: Apr. 14, 2003; Accepted: Aug. 14, 2003 Address for reprints: Dr. Wen-Jen Su, Division of Pediatric Cardiology, Chang Gung Children's Hospital. 5-7, Fushing Street, Gueishan Shiang, Taoyuan, Taiwan 333, R.O.C. Tel.: 886-3-3281200 ext. 8529; Fax: 886-3-3287783

380 Fig. 1 ECG reveals a short PR interval, high QRS voltage, ST-T changes and prominent Q wave in the left precordial leads. was marked hepatomegaly but no splenomegaly. Brachial and femoral pulses were normal. Neither nailbed cyanosis nor clubbing fingers were noted. Flaccid extremities with frog position and decreased deep tendon reflexes were found on neurological examination. Developmental milestones were delayed. His older brother died of hypertrophic cardiomyopathy with congestive heart failure at 5 months of age. Chest films showed cardiomegaly with a cariothoracic ratio of about 80% and hepatomegaly. An ECG (Fig. 1) revealed a short PR interval, high QRS voltage, ST-T changes and prominent Q wave in the left precordial leads. The echocardiogram (Fig. 2) demonstrated bi-ventricular and inter-ventricular hypertrophy but no left ventricular outflow tract obstruction. Pompe disease was confirmed by deficient activity of acid ɗ-glucosidase (GAA) (0.283 units, control 1.203 units). This activity was also decreased in his parents (father 0.620 units, mother 0.412 units). The level of total/free carnitinl, which were 19.13/15.62 nmol/ml, were midly reduceol, as compared with those in control patients (46.3Ų 9.9/39.8Ų8.6 nmol/ml). Increased levels of glutamic oxaloacetic acid transferase (GOT)--- 377 U/L and Fig. 2 Echocardiogram demonstrates bi-ventricular and inter- ventricular hypertrophy. creatine phosphokinase (CPK)--- 1262 U/L with CPK-MB 2.8% were also found. The levels of pyruvate and lactate (pyruvate/lactate 0.29/19.13 mg/dl) were within the normal range. There was no hypoglycemia. Genetic studies (Fig. 3) revealed point mutation on exon 13 with Gly615Arg. After improvement of his respiratory condition, he was

381 discharged under the medication of digoxin, lasix and carnitine. The patient had progressive cardiorespiratory deterioration despite medical treatment, and he was hospitalized several times because of bronchopneumonia and congestive heart failure. He died of cardiopulmonary failure, aspiration pneumonia and hypertrophic cardiomyopathy at 8 months of age. On autopsy, histopathologic examination revealed vacuolar changes in all skeletal muscles and the myocardium (Fig. 4A), and marked ballooning changes in the neurons of the spinal cord (Fig. 4B) and medulla, but the cortex was spared. Periodic acid- Schiff (PAS) stain of the neurons in the spinal cord (Fig. 4C) was strongly positive, and PAS with diesterase stain was negative, which confirmed abundant glycogen deposition. Electronic microscopic examination of hepatocytes revealed glycogen deposition in multiple membrane-bound nodules. The whole pictures were compatible with Type II glycogen storage disease (Pompe disease). Genetic studies of the myocardium and skeletal muscle also showed mutation of the specific gene for acid-maltase at exon 13. The lung showed mild multifocal bronchopneumonia, secondary to severe heart failure and poor motor function. Fig. 3 DNA sequencing reveals point mutations on exon 13 of Gly615Arg.

A B C Fig. 4 Pathological examinations demonstrate vacuolar changes in the myocardium ((A) H & E stain, 100Ű) and ballooning changes in the motor neurons of the spinal cord ((B) H&E stain, 400Ű). PAS stain of the neurons ((C) 400Ű) is strongly positive. 382 DISCUSSION The differential diagnosis of hypertrophic cardiomyopathy in an infant includes familial hypertrophic cardiomyopathy, corticosteroid or catecholamine excess, storage disorder, tumor infiltration, outflow tract obstruction from anatomical valvular or vascular lesions and mitochondrial respiratory chain enzyme abnormalities. (2,3) Our patient appeared healthy at birth but gradually experienced macroglossia, hepatomegaly, massive cardiomegaly, and general muscle weakness with weak crying and feeding difficulties. His older brother died of hypertrophic cardiomyopathy with congestive heart failure at 5 months of age. The clinical features and family history were compatible with GSD-II, and genetic studies further confirmed the diagnosis. The short PR interval on EKG may resulted from facilitating nerve conduction due to glycogen deposits. High QRS voltage is consistent with cardiomegaly. ST-T changes with a prominent Q in the left precordial leads may be signs of a "strain" pattern or ischemic changes.(3) Pompe disease is caused by mutations in the GAA gene. Multiple types of mutations in the GAA gene (locus on 17q23) have been reported worldwide. (4) The GAA genetic study in our patient demonstrated site mutation on exon 13, ie, Gly615Arg. The parents of our patient both carried the recessive gene. A child of two heterozygous parents has a 25% chance of being homozygous. Prenatal genetic diagnosis is done using amniocytes or chorionic villi,(5) and genetic counseling for the family is necessary. The histological findings in the nervous system of our patient showed marked deposition of glycogen on the neurons of the anterior horn of the spinal cord and medulla, but the cortex was spared. These may explain the clinical features of poor motor function, and decreased deep tendon reflexes and lack of mental retardation in this disease. The reason why the cerebral cortex was not involved is unknown, and has not been mentioned in previous articles. Electron microscopic examination of hepatocytes reveals glycogen deposition in multiple membrane-bound nodules.(6) Fat staining is focally positive. Lipid accumulation and mildly reduced concentrations of carnitine in infantile Pompe disease have

383 been reported. (7) We prescribed carnitine for the patient to correct the deficiency, improve fatty acid metabolism and retard the rapid deterioration of cardiopulmonary function. In this article, we reported on a patient with infantile-onset GSD-II. Comprehensive studies included a typical clinical appearance, chest roentgenogram, EKG, echocardiograms, genetic diagnosis and pathological findings. Carnitine supplements may be of benefit for the patient with infantile Pompe disease with carnitine deficiency until the safety and efficacy of rhgaa enzyme therapy has been well documented. REFERENCES 1. Jordan DM, Ellen RE, Charles IB. An interesting case of infant sudden death: severe hypertrophic cardiomyopathy in Pompe's disease. PACE 1999;22:821-2. 2. Gottesman GS, Hoffmann JW, Vogler C, Chen SC. Hypertrophic cardiomyopathy in a newborn infant. J of Pediatr 1999;134:114-8. 3. Hugh DA, Howard PG, Edward BC, David JD. Moss and Adams' Heart Disease in Infants, Children, and Adolescents. Lippincott Williams and Wilkins, 2001: 1167-86. 4. Ko TM, Hwu WL, Lin YW. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 1999;13:380-4. 5. Kleijer WJ, van der Kraan M, Kroos MA. Prenatal diagnosis of glycogen storage disease type II: enzyme assay or mutation analysis? Pediatr Res 1995;38:103-6. 6. Griffin JL. Infantile acid maltase deficiency. III. Ultrastructure of metachromatic material and glycogen in muscle fibers. Virchows Archiv B Cell Pathol Incl Mol Pathol 1984;45:51-61. 7. Verity MA. Infantile Pompe's disease, lipid storage, and partial carnitine deficiency. Muscle Nerve 1991;14:435-40.

384 1 2 ( ) (lysosome) acid α-glucosidase 8 acid α-glucosidase acid α-glucosidase 2004;27:379-84) ( acid α-glucosidase 1 2 92 4 14 92 8 14 333 5-7 Tel.: (03)3281200 8259; Fax: (03)3287783